Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Wyndaele
Jean Jacques
JJ
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D009929:Organ Size / Q000187:drug effects; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011467:Prostate / Q000033:anatomy & histology*; D012449:Safety; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D000068737:Tolterodine Tartrate; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000473:pathology; D014570:Urologic Diseases / Q000188:drug therapy* / Q000473:pathology
D000317:Adrenergic alpha-Antagonists; D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018721:Muscarinic Agonists; D013449:Sulfonamides; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000077409:Tamsulosin